Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. R. Monserrate Mitchell, E. Prats Soro, M. Lopez Sanchez, F. Manresa Presas (Spain). Pseudomonas aeruginosa and antibiotic resistance in acute exacerbations of COPD (AECOPD). Eur Respir J 2009; 34: Suppl. 53, 1365

Member's Comments

No comment yet.

Related content which might interest you: Pseudomonas aeruginosa drug susceptibility in patients hospitalized with COPD exacerbation and bronchiectasis Source: Eur Respir J 2001; 18: Suppl. 33, 541s Year: 2001 Acute exacerbations of COPD due to pseudomonas aeruginosa: Impact of antimicrobial resistance Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance Year: 2015 Severe exacerbations of chronic obstructive pulmonary disease (COPD) due to Pseudomonas aeruginosa: resistance to common antibiotics Source: Eur Respir J 2001; 18: Suppl. 33, 540s Year: 2001 Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study Source: Eur Respir J 2009; 34: 1072-1078 Year: 2009 The impact of pseudomonas aeruginosa in the sputum of patients presenting with acute COPD exacerbation Source: Annual Congress 2004 - Role of infection in COPD Year: 2004 COPD and pseudomonas aeruginosa, an association Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014 The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020 Influence of biofim on the bronchial microbiome in COPD patients colonized or infected by pseudomonas aeruginosa Source: International Congress 2015 – Advances from translational research in respiratory infections Year: 2015 Impact of Pseudomonas aeruginosa on exacerbation and death in patients with chronic obstructive pulmonary disease. Source: International Congress 2019 – Airway infection in COPD Year: 2019 Inhaled corticosteroid use and its association with Pseudomonas aeruginosa infection in COPD Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Bacterial infections in patients with acute exacerbations of COPD Source: Eur Respir J 2004; 24: Suppl. 48, 639s Year: 2004 Inhaled phage therapy for the treatment of acute Pseudomonas aeruginosa lung infections Source: International Congress 2018 – Mechanisms of respiratory infection Year: 2018 Antibacterial activity of telithromycin (TEL) and comparators against bacterial pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in the PROTEKT study 1999–2002 Source: Eur Respir J 2004; 24: Suppl. 48, 641s Year: 2004 Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with acute exacerbations of chronic bronchitis (AECB) in PROTEKT years 1–5 (1999–2004) Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients Year: 2006 Antibiotic treatment and prevention of exacerbations of COPD Source: Eur Respir Monogr 2013; 60: 96-106 Year: 2013 Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD. Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond Year: 2020 Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study Source: Eur Respir J 2013; 41: 1107-1115 Year: 2013 The effect of erythromycin on the chronic lower airway infection by pseudomonas aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 640s Year: 2004 COPD: antibiotic strategy in infectious exacerbations Source: Eur Respir J 2001; 18: Suppl. 33, 137s Year: 2001 Etiology of exacerbations in severe COPD patients with bronchial chronic colonization by pseudomonas Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013